A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma

NCT07713290 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Unresectable Hepatocellular Cancer

Interventions

DRUG: GKL-006 Injection
PROCEDURE: Transarterial chemoembolization (TACE)

Sponsor

Beijing Gene Key Life Technology Co., Ltd